[{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces Completion of Scientific Advice Meeting with the Dutch Medicines Evaluation Board","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dirocaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients\n","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dirocaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-129","moa":"CFTR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Proteostasis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteostasis Therapeutics \/ Yumanity Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Proteostas.."}]

Find Clinical Drug Pipeline Developments & Deals by Proteostasis Therapeutics

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Proteostasis Therapeutics

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

INTERVIEW #SpeakPharma, VLOG #PharmaReel, DATA COMPILATION #PharmaFlow, 10 NEWS #PharmaBuzz

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Proteostasis Therapeutics

U.S.A

26th North American ISSX

Not Confirmed

02

Proteostasis Therapeutics

U.S.A

26th North American ISSX

Not Confirmed

03

Proteostasis Therapeutics

U.S.A

26th North American ISSX

Not Confirmed

04

Proteostasis Therapeutics

U.S.A

26th North American ISSX

Not Confirmed

05

Proteostasis Therapeutics

U.S.A

26th North American ISSX

Not Confirmed